Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Francesco Carubbi, Rosaria Fidanza, Maria Palmieri, Alessandra Ventura, Sara Tambone, Paola Cipriani, Roberto Giacomelli & Maria Concetta Fargnoli. (2020) Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. Journal of Dermatological Treatment 31:7, pages 692-697.
Read now
Read now
Dario Kivelevitch, Bobbak Mansouri & Alan Menter. (2014) Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis. Biologics: Targets and Therapy 8, pages 169-182.
Read now
Read now
Muhammad Haroon, Oliver FitzGerald & Robert Winchester. (2013) Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options. Psoriasis: Targets and Therapy 3, pages 11-23.
Read now
Read now
Gino A. Vena, Nicoletta Cassano, Stefano Piaserico, Andrea Conti & Giampiero Girolomoni. (2012) Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. Immunopharmacology and Immunotoxicology 34:6, pages 901-906.
Read now
Read now
Todd A Kerensky, Alice B Gottlieb, Shimrat Yaniv & Shiu-chung Au. (2012) Etanercept: efficacy and safety for approved indications. Expert Opinion on Drug Safety 11:1, pages 121-139.
Read now
Read now
Articles from other publishers (17)
Jacob A. Mojeski & Robert E. Kalb. 2021. Advances in Psoriasis. Advances in Psoriasis
173
199
.
Joseph F. Merola, Benjamin Lockshin & Elinor A. Mody. (2017) Switching biologics in the treatment of psoriatic arthritis. Seminars in Arthritis and Rheumatism 47:1, pages 29-37.
Crossref
Crossref
Bernard Combe, Frank Behrens, Neil McHugh, Fiona Brock, Urs Kerkmann, Blerina Kola & Gaia Gallo. (2016) Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials. The Journal of Rheumatology 43:6, pages 1063-1067.
Crossref
Crossref
Tristan Boyd & Arthur Kavanaugh. (2015) Novel Treatment Concepts in Psoriatic Arthritis. Rheumatic Disease Clinics of North America 41:4, pages 739-754.
Crossref
Crossref
Suzanne J. Tintle & Alice B. Gottlieb. (2015) Psoriatic Arthritis for the Dermatologist. Dermatologic Clinics 33:1, pages 127-148.
Crossref
Crossref
Jennifer C. Cather & Jeffrey J. Crowley. (2014) Use of Biologic Agents in Combination with Other Therapies for the Treatment of Psoriasis. American Journal of Clinical Dermatology 15:6, pages 467-478.
Crossref
Crossref
Maria Laura Acosta Felquer, Laura C. Coates, Enrique R. Soriano, Roberto Ranza, Luis R. Espinoza, Philip S. Helliwell, Oliver FitzGerald, Neil McHugh, Euthalia Roussou & Philip J. Mease. (2014) Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. The Journal of Rheumatology 41:11, pages 2277-2285.
Crossref
Crossref
Ashley L. Semble, Scott A. Davis & Steven R. Feldman. (2013) Safety and Tolerability of Tumor Necrosis Factor-α Inhibitors in Psoriasis: A Narrative Review. American Journal of Clinical Dermatology 15:1, pages 37-43.
Crossref
Crossref
Dagmar Wilsmann-Theis, Kristina Fronhoffs, Lin-Kristin Ehler, Joerg Wenzel, Thomas Bieber & Karin Klingmueller. (2014) Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris. Dermatologic Therapy 27:1, pages 55-59.
Crossref
Crossref
Cerrene N. Giordano & Robert E. Kalb. 2014. Advances in Psoriasis. Advances in Psoriasis
177
196
.
Emily Yiping Gan, Wei-Sheng Chong & Hong Liang Tey. (2013) Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents. BioDrugs 27:4, pages 359-373.
Crossref
Crossref
M. D. Colombo, N. Cassano, G. Bellia & G. A. Vena. (2013) Cyclosporine Regimens in Plaque Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment Approaches. The Scientific World Journal 2013, pages 1-11.
Crossref
Crossref
G.A. Vena, V. Mastrandrea, S. Battaglini, F. Loconsole, R. Buquicchio & N. Cassano. (2017) Combination of Etanercept and Twice-Weekly Administration of Cyclosporin in Psoriasis Unsatisfactorily Controlled by Etanercept Monotherapy: A Retrospective Analysis. European Journal of Inflammation 10:2, pages 239-242.
Crossref
Crossref
MATTEO NICOLA DARIO Di MINNO, SALVATORE IERVOLINO, ROSARIO PELUSO, ANNA RUSSOLILLO, ROBERTA LUPOLI, RAFFAELE SCARPA, GIOVANNI Di MINNO & GIOVANNI TARANTINO. (2012) Hepatic Steatosis and Disease Activity in Subjects with Psoriatic Arthritis Receiving Tumor Necrosis Factor-α Blockers. The Journal of Rheumatology 39:5, pages 1042-1046.
Crossref
Crossref
Kristian Reich, Silja Domm & Ulrich Mrowietz. (2012) Methotrexate therapy in dermatology. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 10:5, pages 363-370.
Crossref
Crossref
R.G. Langley. (2012) Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?. Journal of the European Academy of Dermatology and Venereology 26, pages 21-29.
Crossref
Crossref
GEORGE N. KARANIKOLAS, EFTYHIA-MARIA KOUKLI, AIKATERINI KATSALIRA, AIKATERINI ARIDA, DIMITRIOS PETROU, ELENI KOMNINOU, KALLIOPI FRAGIADAKI, ANNA ZACHARIOUDAKI, IOANNIS LASITHIOTAKIS, EIRINI GIAVRI, GEORGE VAIOPOULOS & PETROS P. SFIKAKIS. (2011) Adalimumab or Cyclosporine as Monotherapy and in Combination in Severe Psoriatic Arthritis: Results from a Prospective 12-month Nonrandomized Unblinded Clinical Trial. The Journal of Rheumatology 38:11, pages 2466-2474.
Crossref
Crossref